A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.

Hdl Handle:
http://hdl.handle.net/10147/189007
Title:
A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.
Authors:
Dee, Anne; Howell, Fenton
Affiliation:
Health Service Executive Mid-West Region, 31/33 Catherine Street, Limerick, Ireland. anne.dee1@hse.ie
Citation:
A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. 2010, 20 (2):213-9 Eur J Public Health
Journal:
European journal of public health
Issue Date:
Apr-2010
URI:
http://hdl.handle.net/10147/189007
DOI:
10.1093/eurpub/ckp141
PubMed ID:
19864366
Additional Links:
http://eurpub.oxfordjournals.org/content/20/2/213.full
Abstract:
Cervical cancer is a leading cause of death worldwide, and in Ireland it is the ninth most commonly diagnosed cancer in women. Almost 100% of these cancers are caused by human papillomavirus (HPV) infection. Two newly developed vaccines against HPV infection have become available. This study is a cost-utility analysis of the HPV vaccine in Ireland, and it compares the cost-effectiveness profiles of the two vaccines.; A cost-utility analysis of the HPV vaccine in Ireland was performed using a Markov model. A cohort of screened and vaccinated women was compared with an unvaccinated screened cohort, and both cohorts were followed over their lifetimes. The model looked at uptake of services related to HPV disease in both cohorts. Outcomes were measured in quality adjusted life years (QALYs). Extensive sensitivity analysis was done.; For the base case analysis, the model showed that the incremental cost-effectiveness ratio (ICER) for quadrivalent HPV vaccination would be 25,349 euros/QALY and 30,460 euros/QALY for the bivalent vaccine. The ICER for the quadrivalent vaccine ranged from 2877 euros to 36,548 euros, and for the bivalent from 3399 euros to 45,237 euros. At current prices, the bivalent vaccine would need to be 22% cheaper than the quadrivalent vaccine in order to have equivalent cost effectiveness.; HPV vaccination has the potential to be very cost effective in Ireland. The quadrivalent vaccine is more cost effective than the bivalent vaccine.
Item Type:
Article
Language:
en
Keywords:
HEALTH PROTECTION; IMMUNISATION
Local subject classification:
PUBLIC HEALTH DEPARTMENT; HEALTH SERVICE PLANNING
MeSH:
Cost-Benefit Analysis; Costs and Cost Analysis; Early Detection of Cancer; Female; Humans; Ireland; Markov Chains; Papillomavirus Infections; Papillomavirus Vaccines; Uterine Cervical Neoplasms; Vaccination
ISSN:
1464-360X

Full metadata record

DC FieldValue Language
dc.contributor.authorDee, Anneen
dc.contributor.authorHowell, Fentonen
dc.date.accessioned2011-11-08T09:46:41Z-
dc.date.available2011-11-08T09:46:41Z-
dc.date.issued2010-04-
dc.identifier.citationA cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. 2010, 20 (2):213-9 Eur J Public Healthen
dc.identifier.issn1464-360X-
dc.identifier.pmid19864366-
dc.identifier.doi10.1093/eurpub/ckp141-
dc.identifier.urihttp://hdl.handle.net/10147/189007-
dc.description.abstractCervical cancer is a leading cause of death worldwide, and in Ireland it is the ninth most commonly diagnosed cancer in women. Almost 100% of these cancers are caused by human papillomavirus (HPV) infection. Two newly developed vaccines against HPV infection have become available. This study is a cost-utility analysis of the HPV vaccine in Ireland, and it compares the cost-effectiveness profiles of the two vaccines.-
dc.description.abstractA cost-utility analysis of the HPV vaccine in Ireland was performed using a Markov model. A cohort of screened and vaccinated women was compared with an unvaccinated screened cohort, and both cohorts were followed over their lifetimes. The model looked at uptake of services related to HPV disease in both cohorts. Outcomes were measured in quality adjusted life years (QALYs). Extensive sensitivity analysis was done.-
dc.description.abstractFor the base case analysis, the model showed that the incremental cost-effectiveness ratio (ICER) for quadrivalent HPV vaccination would be 25,349 euros/QALY and 30,460 euros/QALY for the bivalent vaccine. The ICER for the quadrivalent vaccine ranged from 2877 euros to 36,548 euros, and for the bivalent from 3399 euros to 45,237 euros. At current prices, the bivalent vaccine would need to be 22% cheaper than the quadrivalent vaccine in order to have equivalent cost effectiveness.-
dc.description.abstractHPV vaccination has the potential to be very cost effective in Ireland. The quadrivalent vaccine is more cost effective than the bivalent vaccine.-
dc.language.isoenen
dc.relation.urlhttp://eurpub.oxfordjournals.org/content/20/2/213.fullen
dc.subjectHEALTH PROTECTIONEN
dc.subjectIMMUNISATIONEN
dc.subject.meshCost-Benefit Analysis-
dc.subject.meshCosts and Cost Analysis-
dc.subject.meshEarly Detection of Cancer-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshIreland-
dc.subject.meshMarkov Chains-
dc.subject.meshPapillomavirus Infections-
dc.subject.meshPapillomavirus Vaccines-
dc.subject.meshUterine Cervical Neoplasms-
dc.subject.meshVaccination-
dc.subject.otherPUBLIC HEALTH DEPARTMENTEN
dc.subject.otherHEALTH SERVICE PLANNINGEN
dc.titleA cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.en
dc.typeArticleen
dc.contributor.departmentHealth Service Executive Mid-West Region, 31/33 Catherine Street, Limerick, Ireland. anne.dee1@hse.ieen
dc.identifier.journalEuropean journal of public healthen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.